ATE527237T1 - Modifizierter mscl-proteinkanal - Google Patents
Modifizierter mscl-proteinkanalInfo
- Publication number
- ATE527237T1 ATE527237T1 AT04808728T AT04808728T ATE527237T1 AT E527237 T1 ATE527237 T1 AT E527237T1 AT 04808728 T AT04808728 T AT 04808728T AT 04808728 T AT04808728 T AT 04808728T AT E527237 T1 ATE527237 T1 AT E527237T1
- Authority
- AT
- Austria
- Prior art keywords
- channel
- light
- responsive
- compounds
- protein channel
- Prior art date
Links
- 108091006146 Channels Proteins 0.000 abstract 7
- 102000034573 Channels Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000012377 drug delivery Methods 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/04—Thiosulfonates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078718A EP1535903A1 (de) | 2003-11-25 | 2003-11-25 | Modifizierter MSCL-Protein-Kanal |
| PCT/NL2004/000812 WO2005051902A2 (en) | 2003-11-25 | 2004-11-25 | MODIFIED MscL PROTEIN CHANNEL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE527237T1 true ATE527237T1 (de) | 2011-10-15 |
Family
ID=34442990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04808728T ATE527237T1 (de) | 2003-11-25 | 2004-11-25 | Modifizierter mscl-proteinkanal |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7393828B2 (de) |
| EP (2) | EP1535903A1 (de) |
| AT (1) | ATE527237T1 (de) |
| DK (1) | DK1687267T3 (de) |
| WO (1) | WO2005051902A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1535903A1 (de) | 2003-11-25 | 2005-06-01 | Applied NanoSystems B.V. | Modifizierter MSCL-Protein-Kanal |
| EP1832575A1 (de) * | 2006-03-06 | 2007-09-12 | Sulfidris S.r.l. | Entzündungshemmende Mittel |
| US20100189777A1 (en) * | 2007-07-20 | 2010-07-29 | Basf Se | Functionalized nanocompartments with a transport system |
| US9557635B2 (en) | 2007-10-18 | 2017-01-31 | Gearbox, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8529426B2 (en) | 2007-10-18 | 2013-09-10 | The Invention Science Fund I Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8164074B2 (en) | 2007-10-18 | 2012-04-24 | The Invention Science Fund I, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8227204B2 (en) | 2007-10-18 | 2012-07-24 | The Invention Science Fund I, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8168958B2 (en) | 2007-10-18 | 2012-05-01 | The Invention Science Fund I, Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US20090104113A1 (en) * | 2007-10-18 | 2009-04-23 | Searete Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| US8684898B2 (en) | 2007-10-18 | 2014-04-01 | The Invention Science Fund I Llc | Ionizing-radiation-responsive compositions, methods, and systems |
| EP2127640A1 (de) * | 2008-05-27 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Modifizierte azid-enthaltende Proteine |
| US9345113B2 (en) | 2009-06-24 | 2016-05-17 | Koninklijke Philips N.V. | Method and device for programming a microcontroller |
| PL213159B1 (pl) | 2010-04-23 | 2013-01-31 | Inst Biolog Doswiadczalnej Im Marcelego Nenckiego Pan | Zmutowane szczepy Escherichia coli, sposób testowania potencjalnych zwiazków antybakteryjnych wykorzystujacy te szczepy oraz zestaw do testowania |
| WO2014081300A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| CN111801232B (zh) * | 2018-01-29 | 2023-12-15 | 法雷奥气候控制公司 | 用于电动车辆的hvac模块 |
| CN120314408A (zh) * | 2021-08-30 | 2025-07-15 | 四川大学 | 一种MtMscL纳米孔系统在检测多肽中的应用 |
| CN114854431B (zh) * | 2022-05-24 | 2023-06-13 | 江南大学 | 一种基于动态共价键的智能Pickering乳状液及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2743260A (en) * | 1953-05-25 | 1956-04-24 | Us Rubber Co | Polymeric methyeol maleimide and derivatives |
| NL247005A (de) * | 1959-01-05 | |||
| DE2100440A1 (de) * | 1971-01-07 | 1972-07-20 | Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt | Maleinimide und Verfahren zu ihrer Herstellung |
| US4011327A (en) * | 1975-01-31 | 1977-03-08 | Research Corporation | Compositions containing 7β-alkylthiodeoxynupharadin-6α-ols |
| EP1535903A1 (de) | 2003-11-25 | 2005-06-01 | Applied NanoSystems B.V. | Modifizierter MSCL-Protein-Kanal |
-
2003
- 2003-11-25 EP EP03078718A patent/EP1535903A1/de not_active Withdrawn
-
2004
- 2004-11-25 AT AT04808728T patent/ATE527237T1/de not_active IP Right Cessation
- 2004-11-25 EP EP04808728A patent/EP1687267B1/de not_active Expired - Lifetime
- 2004-11-25 WO PCT/NL2004/000812 patent/WO2005051902A2/en not_active Ceased
- 2004-11-25 DK DK04808728.2T patent/DK1687267T3/da active
-
2006
- 2006-05-19 US US11/437,873 patent/US7393828B2/en not_active Expired - Fee Related
-
2007
- 2007-10-29 US US11/978,743 patent/US7608582B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005051902A3 (en) | 2005-10-27 |
| WO2005051902A2 (en) | 2005-06-09 |
| EP1535903A1 (de) | 2005-06-01 |
| EP1687267A2 (de) | 2006-08-09 |
| EP1687267B1 (de) | 2011-10-05 |
| DK1687267T3 (da) | 2012-01-23 |
| US7608582B2 (en) | 2009-10-27 |
| US7393828B2 (en) | 2008-07-01 |
| WO2005051902A8 (en) | 2005-08-11 |
| US20060258587A1 (en) | 2006-11-16 |
| US20080138401A1 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE527237T1 (de) | Modifizierter mscl-proteinkanal | |
| WO2005046709A3 (en) | Tgf - beta binding and supported peptides | |
| WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
| EA200700391A1 (ru) | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 | |
| AU2003228962A1 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| MY154826A (en) | Fusion protein capable of binding vegf | |
| HK1210713A1 (en) | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof | |
| CY1118930T1 (el) | Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων | |
| ATE397016T1 (de) | Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen | |
| WO2006052821A3 (en) | Compositions and methods for treatment of protein misfolding and protein aggregation diseases | |
| FR2857267B1 (fr) | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. | |
| ATE368687T1 (de) | Thrombopoietinproteine mit verbesserten eigenschaften | |
| WO2006000213A3 (de) | Peptide zur inhibition der interaktion von proteinkinase a und proteinkinase a-ankerproteinen | |
| WO2004085461A3 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| AR053285A1 (es) | Tratamiento de enfemedades usando un sistema mejorado de expresion regulada | |
| WO2004113386A3 (en) | Modified hirudin proteins and t-cell epitopes in hirudin | |
| WO2004031222A3 (en) | Dna vaccine encoding at least two nonstructural early proteins of papillomavirus | |
| WO2004050014A3 (en) | Seterocyclic quinones as pharmaceutical agents | |
| WO2005062767A3 (en) | Hoxd3, hoxa3, and hoxb3 compositions and methods for improved wound healing | |
| NO20072457L (no) | Plasmider som koder for p185neu proteinsekvensvarianter og terapeutisk anvendelse derav | |
| WO2006018450A3 (en) | Pharmaceutically active insulin receptor-modulating molecules | |
| WO2002079222A3 (en) | Fusion proteins for specific treatment of cancer and auto-immune diseases | |
| DOP2006000117A (es) | Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada | |
| AU2004206257A8 (en) | Human SAA3 nucleic acid molecule, protein, and methods of use for same | |
| WO2008070586A3 (en) | Compositions and methods for treatment of protein misfolding and protein aggregation diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |